Novartis, GSK - QVA149- Most Advanced once daily LABA+LAMA: Data positive but Competition follows closely
Today, NVS announced positive clinical data from three PhIII clinical studies (SHINE, BRIGHT & ENLIGHTEN) exploring the efficacy and safety of QVA149. In the SHINE study (26 wk, n=2100), QVA149 showed statistically superior FEV1 reduction in comparison with Indacaterol, NVA237 and tiotropium (open label) in moderate to severe COPD patients. In a smaller BRIGHT study (3 wk), QVA149 demonstrated significant improvement in exercise endurance against placebo and in the ENLIGHTEN study (52 Week safety study), it has achieved similar safety and tolerability profile against placebo.
The 26 week ILLUMINATE study, which compares QVA149 head to head with Seretide will also report data this year and will be important determinant of QVA149 peak sales potential.
The 26 week ILLUMINATE study, which compares QVA149 head to head with Seretide will also report data this year and will be important determinant of QVA149 peak sales potential.
COMPANIES MENTIONED
NOVARTIS, GlaxoSmithKline
NOVARTIS, GlaxoSmithKline
